Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage II Esophageal Cancer Clear all
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage IV Esophageal Cancer AJCC v7
Interventions
Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
233
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 173 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 4:39 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Itraconazole
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced May 21, 2026, 4:39 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Appendix Cancer, Stomach Cancer, Gallbladder Cancer, Liver Cancer, Small Intestine Cancer, Large Intestine Cancer, Anal Cancer, Biliary Tract Cancer, Gastrointestinal Stromal Cancer
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration, Yoga Skills Training, Attention Control, Actigraphy Assessment
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Cancer of the Esophagus, Esophagus Cancer, Esophageal Neoplasm, Cancer of Esophagus
Interventions
Irinotecan (drug), Taxotere (drug), Radiotherapy (procedure), Esophagectomy (procedure)
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced May 21, 2026, 4:39 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer
Interventions
irinotecan, cisplatin, celecoxib
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced May 21, 2026, 4:39 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreas Adenocarcinoma, Duodenal Adenocarcinoma, Ampullary Adenocarcinoma, Gallbladder Adenocarcinoma, Intra - and Extrahepatic Cholangiocarcinoma
Interventions
Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
Procedure · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced May 21, 2026, 4:39 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Interventions
Sequential FLOT followed by chemoradiation
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer, Gastrointestinal Stromal Tumor, HER2-negative Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Cell Lung Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Triple-negative Breast Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, fluorouracil, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
38
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced May 21, 2026, 4:39 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III, Other Cancers in the Thoracic Region
Interventions
MRgART, LINAC
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced May 21, 2026, 4:39 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Interventions
Pembrolizumab, Trastuzumab, ado-trastuzumab emtansine, Cetuximab
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, paclitaxel, surgical procedure
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
28
States / cities
Chicago, Illinois • Evanston, Illinois • Peoria, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced May 21, 2026, 4:39 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
ceritinib
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced May 21, 2026, 4:39 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Esophagogastric Cancer, HER2-Negative
Interventions
regorafenib, nivolumab, FOLFOX chemotherapy with oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
Drug · Other · Radiation + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
634
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 4:39 PM EDT
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
Interventions
Rucaparib, Ramucirumab, Nivolumab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Chicago, Illinois • Fairway, Kansas • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
Interventions
Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Esophageal Cancer
Interventions
bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
Interventions
FOLFOX, 5-FU, Erlotinib
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced May 21, 2026, 4:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced May 21, 2026, 4:39 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
Panitumumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced May 21, 2026, 4:39 PM EDT